title: [The efficacy and safety of daptomycin for the treatment of Gram-positive bacterial infections in Chinese population].
abstract: OBJECTIVE
  To investigate the efficacy and safety of daptomycin in Chinese patients with serious infections of Gram-positive coccus.
  
  
  METHODS
  Clinical data were retrospectively collected from patients who were suspected with Gram-positive coccal infections and received daptomycin treatment between August 2010 and October 2012.
  
  
  RESULTS
  A total of 203 Chinese patients from 26 centers were enrolled in our study, including 94 microbiologically diagnosed. Staphylococcus aureus was the most common pathogen (33%, 31/94) with 45.2% (14/31) methicillin-resistant Staphylococcus aureus (MRSA). According to the infection sites, primary bloodstream infection (45.8%, 93/203) was the most frequent, which was followed by skin and soft tissue infections (15.3%, 31/203). Seventy-seven cases (37.9%, 77/203) had bloodstream infections complicated with other infections (37.9%, 77/203), 13 of which were endocarditis. The clinical efficacy of intention-to-treatment (ITT) and modified ITT (MITT) analysis were 70.44% (143/203) and 78.72% (74/94), respectively. Seven patients (3.4%) represented drug-related adverse effect, but no serious adverse effect was reported. Moderate creatine phosphate kinase (CPK) elevation was observed in 4 patients (2%), which returned to normal range after drug withdrawl.
  
  
  CONCLUSIONS
  Daptomycin is effective and safe for Chinese patients with serious infections of Gram-positive cocci. (registration number NCT10212601).
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Junmin
authors.initials: J
authors.lastname: Li
authors.forename: Xianyao
authors.initials: X
authors.lastname: Wan
authors.forename: Jianzhen
authors.initials: J
authors.lastname: Shen
authors.forename: Hong
authors.initials: H
authors.lastname: Liu
authors.forename: Hongmei
authors.initials: H
authors.lastname: Gao
authors.affiliation: Department of Infectious Disease, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China; Email: zhengyinl@hotmail.com.
authors.forename: Zhengyin
authors.initials: Z
authors.lastname: Liu
authors.forename: Aixia
authors.initials: A
authors.lastname: Wang
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002681:China / Q000453:epidemiology; D017576:Daptomycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016908:Gram-Positive Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000208:ethnology; D006095:Gram-Positive Cocci / Q000302:isolation & purification*; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus; D012189:Retrospective Studies; D012449:Safety; D013211:Staphylococcus aureus / Q000302:isolation & purification; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin